STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Read full article →Medicare Monitor
Tracking Medicare news, policy, and coverage changes.
Alcohol study discarded by Trump officials is published in scientific journal
A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
Read full article →More Americans survive cancer. But the psychological impacts can persist for years
Due to advancements in treatment and screening, more Americans are surviving cancer. But many are left with lingering mental health challenges like anxiety and depression.
Read full article →GLP-1s appear to protect against cancer. Researchers are trying to figure out how
Recent studies suggest GLP-1s, the weight loss and diabetes drugs, may both prevent cancer and slow its progression. While weight loss is known to curb cancer risks, GLP-1s may act on other brain and metabolic pathways to prevent cancer.
Read full article →HHS Affordability Czar Says Healthcare Costs Stem From Incentives, Not Coverage
Healthcare affordability czar Casey Mulligan laid out the economic philosophy guiding the Trump administration’s approach to healthcare costs during a recent conference address. He argued that provider taxes and state-directed payments inflate healthcare spending far beyond Medicaid and ultimately raise costs for employers and taxpayers. The post HHS Affordability Czar Says Healthcare Costs Stem From Incentives, Not Coverage appeared first on MedCity News .
Read full article →Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product. The post Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug appeared first on MedCity News .
Read full article →Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
Read full article →STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Read full article →Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD
(MedPage Today) -- NEW ORLEANS -- Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of...
Read full article →Flesh-Eating Cattle Parasite Spreads Beyond Texas as New Screwworm Cases Are Found
(MedPage Today) -- Two more cases of the New World screwworm have been confirmed, including one outside the main cluster in Texas, demonstrating the difficulty of stopping a pest that could potentially devastate the nation's cattle industry, the...
Read full article →NICU Babies More Likely to Miss Rotavirus Vax
(MedPage Today) -- For U.S. kids born after the rotavirus vaccine was introduced, recommendations against administration in the neonatal intensive care unit (NICU) appeared to be a strong barrier to getting immunized, researchers reported. Children...
Read full article →Primitive Reflexes May Predict Dementia
(MedPage Today) -- Primitive or regressive reflexes -- known as frontal release signs -- later in life were associated with increased dementia risk, a longitudinal study of cognitively normal older adults showed. In adults with intact cognition...
Read full article →